PDF(Pubmed)
Abstract：
OBJECTIVE: The purpose of this review is two-fold: (1) to discuss a case report of idiopathic intracranial hypertension (IIH) after abrupt cessation of a glucagon-like peptide-1 (GLP-1) receptor agonist with resultant rapid weight gain and (2) to review the literature regarding the potential role of GLP-1 receptor agonists in the treatment of IIH as well as potential pitfalls.
RESULTS: GLP-1 receptor agonists have become widely used to treat obesity. Obesity is a known risk factor for the development of IIH, though the precise pathophysiology is unclear. GLP-1 receptor agonists may help treat IIH by promoting weight loss, lipolysis of adipose tissue, and potentially decreasing the secretion of CSF, as was seen in rat models. Abrupt cessation of GLP-1 receptor agonists can result in regaining lost weight rapidly. In the case that we present, the patient stopped duraglutide abruptly due to lack of insurance coverage and regained the weight she had lost within a month. She subsequently developed IIH. GLP-1 receptor agonists have the potential to help treat IIH; however, this class of medication needs to be used carefully, as cessation of the medication and resultant rapid weight gain can result in IIH.
RESULTS: GLP-1 receptor agonists have become widely used to treat obesity. Obesity is a known risk factor for the development of IIH, though the precise pathophysiology is unclear. GLP-1 receptor agonists may help treat IIH by promoting weight loss, lipolysis of adipose tissue, and potentially decreasing the secretion of CSF, as was seen in rat models. Abrupt cessation of GLP-1 receptor agonists can result in regaining lost weight rapidly. In the case that we present, the patient stopped duraglutide abruptly due to lack of insurance coverage and regained the weight she had lost within a month. She subsequently developed IIH. GLP-1 receptor agonists have the potential to help treat IIH; however, this class of medication needs to be used carefully, as cessation of the medication and resultant rapid weight gain can result in IIH.
摘要：
目的：这篇综述的目的有两个：（1）讨论胰高血糖素样肽1（GLP-1）受体激动剂突然停止后特发性颅内高压（IIH）的病例报告。导致体重迅速增加；（2）回顾有关GLP-1受体激动剂在治疗IIH中的潜在作用以及潜在陷阱的文献。
结果：GLP-1受体激动剂已广泛用于治疗肥胖症。肥胖是IIH发展的已知危险因素，尽管确切的病理生理学尚不清楚。GLP-1受体激动剂可能通过促进体重减轻来帮助治疗IIH，脂肪组织的脂解，并可能减少脑脊液的分泌，正如在大鼠模型中看到的那样。突然停止GLP-1受体激动剂可导致快速恢复体重减轻。在我们介绍的情况下，由于缺乏保险，患者突然停止了杜拉鲁肽，并在一个月内恢复了体重减轻。她随后发展了IIH。GLP-1受体激动剂有可能帮助治疗IIH；然而，这类药物需要小心使用，停止药物治疗并导致体重快速增加可能导致IIH。
结果：GLP-1受体激动剂已广泛用于治疗肥胖症。肥胖是IIH发展的已知危险因素，尽管确切的病理生理学尚不清楚。GLP-1受体激动剂可能通过促进体重减轻来帮助治疗IIH，脂肪组织的脂解，并可能减少脑脊液的分泌，正如在大鼠模型中看到的那样。突然停止GLP-1受体激动剂可导致快速恢复体重减轻。在我们介绍的情况下，由于缺乏保险，患者突然停止了杜拉鲁肽，并在一个月内恢复了体重减轻。她随后发展了IIH。GLP-1受体激动剂有可能帮助治疗IIH；然而，这类药物需要小心使用，停止药物治疗并导致体重快速增加可能导致IIH。
